HSD-016

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Healthy Subjects

Phase 1

Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016

CompletedNCT00739232

Wyeth is now a wholly owned subsidiary of PfizerHealthy Subjects

Start: 2008-09-30End: 2009-02-28Target: 74Updated: 2009-08-03

Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016

CompletedNCT00740649

Wyeth is now a wholly owned subsidiary of PfizerHealthy Subjects

Start: 2008-10-31End: 2009-03-31Target: 74Updated: 2009-03-31

Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016

CompletedNCT00838461

Wyeth is now a wholly owned subsidiary of PfizerHealthy Subjects

Start: 2009-03-31End: 2009-06-30Target: 32Updated: 2009-08-03